Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gilead

- PMLiVE

Janssen scores another expansion for new Darzalex combination in the US

Myeloma med approved in combination with Amgen's Kyprolis

- PMLiVE

Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Disruption to uptake of HIV and hepatitis C drugs caused by pandemic

- PMLiVE

Gilead makes a play for novel cancer drug with Tizona deal

Pharma company continues oncology biotech spending spree

If our patients are diverse, why are clinical trials so white?

Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue...

Blue Latitude Health

- PMLiVE

Gilead and Arcus complete closing of ten-year immunotherapy partnership

Deal emphasises Gilead's focus on immuno-oncology

- PMLiVE

Gilead reports remdesivir cuts risk of death in severe COVID-19 patients

Also reveals new analyses from compassionate use programme

- PMLiVE

UPDATED: Gilead drops remdesivir’s orphan drug designation

Decision comes amid intense public criticism of the regulatory status

- PMLiVE

Gilead halts individual requests for COVID-19 hopeful remdesivir

Will now focus on expanded access programmes and backlog

- PMLiVE

Gilead drug reduces HIV viral reservoir, says researcher

Treatment with drug was associated with longer viral suppression

- PMLiVE

BMS, AbbVie’s Empliciti flunks trial in first-line multiple myeloma

Combination regimen didn't improve progression-free survival

Sanofi reception

FDA approves Sanofi’s key cancer drug Sarclisa for myeloma

First cancer drug wholly owned by company to be approved in past decade

- PMLiVE

Gilead swoops on Forty Seven with $4.9bn all-cash deal

Takeover is latest in a string of billion-plus deals signed by Gilead

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links